Getting your Trinity Audio player ready...

Intelligent Bio Solutions Inc. (Nasdaq: INBS), a leading medical diagnostic company known for its fast, innovative, and non-invasive testing solutions, announced the addition of several key client accounts in the United Kingdom manufacturing sector on July 9, 2024.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) stock is currently trading above its 10- and 20-day moving averages, indicating a reversal in a slight uptrend. It closed up 3.21% on Monday, July 15, 2024, on lower-than-average volume, making this stock worth monitoring.

These Prominent manufacturer(s), have transitioned from third-party urine testing to the Intelligent Bio Solutions’ “Fingerprinting Drug Screening System”:

  • An automotive components manufacturer, operating five (5) sites with 1,200 employees
  • A major packaging manufacturer with four (4) sites and approximately 900 employees.
  • A renowned beverage manufacturer with two (2) sites and 350 employees.

Intelligent Bio Solutions’ “Fingerprint Drug Screening System” is an optimal solution for fast and dependable testing. The quick, non-invasive method allows companies to efficiently test their staff. INBS’s cutting-edge Drug Screening System delivers a value-added advantage, tackling safety concerns with precise, on-the-spot testing.

The Intelligent Fingerprinting Drug Screening System detects prevalent drugs of abuse, such as cannabis, opiates, cocaine, and methamphetamine, using sweat from the fingertips. This approach offers a swift, non-invasive alternative to traditional methods, ensuring employees are “Fit to Work.”

Intelligent Bio Solutions Inc. (Nasdaq: INBS) was recently highlighted alongside Trump Media (NASDAQ: DJT), Peraso Inc. (NASDAQ: PRSO), Dyadic International, Inc. (NASDAQ: DYAI), and Catheter Precision, Inc. (NYSE American: VTAK). These stocks have demonstrated recent growth and exhibit promising developments in their respective fields. ​Read entire news article now.